BioSymetrics CSO and head of Life Sciences, Gabe is expanding BioSymetrics’ scientific leadership in biopharma R&D informatics, precision medicine, drug compound HTL generation, genomics, imaging and clinical diagnosis. Previously, Gabe was an Associate Scientist at Brigham and Women’s Hospital where his work focused on using machine learning frameworks to predict gene and small molecule function, and identification of disease-causal genes using large-scale genomic datasets. Gabe received his Ph.D. in Molecular Genetics from the University of Toronto. He also received his Masters of Science and undergraduate degrees from the University of Toronto.
Consortium will expand development of a software platform for genomics and health data and apply it to COVID-19. The $5.1M project, called COVID Cloud, aims to increase Canada’s capacity to harness exponentially growing volumes of genomics and biomedical data to advance precision health.
We are proud to announce that our own Gabe Musso, Chief Science Officer, will be delivering the key note at Hub Xchange's AI in Drug Discovery event on Wednesday, December 2.
Janssen Pharmaceuticals and Sema4 partnership announcement on projects using BioSymetrics Contingent AI platform
“The infrastructure developed by this initiative will propel collaborative Canadian drug discovery efforts for COVID-19,”